TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02366975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel 2%
Description: testosterone gel 2% (50mg/die).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo gel
Study: NCT02098642

Intervention type: OTHER
Intervention: MIRT
Description: A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.

Intervention type: OTHER
Intervention: MIRT
Description: A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.

Intervention type: OTHER
Intervention: Mobilization of the metatarsophalangeal joint of the hallux
Description: MIRT and mobilization of the metatarsophalangeal joint of the hallux
Study: NCT04468620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistive Soft Skills & Employment Training (ASSET)
Description: The ASSET curriculum covers six key social skill areas: (a) Communication; (b) Networking; (c) Attitude \& Enthusiasm; (d) Teamwork; (e) Problem Solving \& Critical Thinking; and (f) Professionalism, as well as new content added based on our pilot findings (Mental Health; Stress Management and Self-Advocacy; and Awareness of Self \& Others). The schedule includes two sessions for Communication and Professionalism, and a graduation session; thus, bringing the total number of sessions to 13. The structural elements of the training format include didactic lecture, experiential activities, group discussions, role-plays, performance feedback,and weekly take-home assignments. A key element is a social hour following each 90-minute session, in which participants practice learned skills while sharing a meal.
Study: NCT04000035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health and work environment information and processes
Description: see arm/group description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health and work environment information and processes
Description: see arm/group description
Study: NCT03387475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: iron chelation
Study: NCT03446391

Intervention type: PROCEDURE
Intervention: Kinematic alignment
Description: The principle for kinematically aligning the femoral component is to remove the correct amount of bone and cartilage from the distal and posterior femur after accounting for wear and saw blade kerf, so that the total thickness of the missing and removed tissue matches the thickness of the femoral component.

Intervention type: PROCEDURE
Intervention: Mechanical alignment
Description: Classic mechanical alignment (MA) in total knee arthroplasty (TKA) is meant to co-align the prosthetic components to the mechanical axes of the femur and tibia and restore neutral overall limb alignment

Intervention type: DEVICE
Intervention: GMK Sphere®
Description: The GMK Sphere® is a total knee prosthesis . The design of the GMK Sphere® is characterized by a spherical medial femoral condyle and an asymmetrical fixed tibial UHMWPE polyethylene insert with a concave spherical medial compartment.

Intervention type: DEVICE
Intervention: GMK Sphere®
Description: The GMK Sphere® is a total knee prosthesis . The design of the GMK Sphere® is characterized by a spherical medial femoral condyle and an asymmetrical fixed tibial UHMWPE polyethylene insert with a concave spherical medial compartment.
Study: NCT04304651

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Limited cancer screening
Description: The limited cancer screening will include: 1) a complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin); and 4) chest X-ray.~In women, a breast examination, Pap smear/pelvic examination (if \< 70 years old and previously sexually active) and mammogram will be performed, if not conducted in last year.~In men, similarly, prostate examination and PSA testing will be performed, if not conducted in the last year.~All patients will undergo colon cancer screening as per local practice.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Limited cancer screening + FDG PET/CT
Description: The limited cancer screening (as described above) in combination with a FDG PET/CT.
Study: NCT02653287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive four individual phone calls focusing on education for SLE disease management, as well as answering any questions the participants have about the study. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Each call will last about 10-15 minutes, and occur shortly after randomization, then at 1.5, 3, and 6 months.
Study: NCT03398525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: usual care following local standard operational procedures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care following local standard operational procedures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musical intervention
Description: Musical intervention using a marketed music program validated for music therapy
Study: NCT02824731

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation with protons

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation with protons

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation with protons

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation with protons

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation with photons

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation with photons

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation with photons

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation with photons
Study: NCT06119009

Intervention type: OTHER
Intervention: non interventions

Intervention type: OTHER
Intervention: non interventions
Study: NCT04093427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: softSTOPP
Description: Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end
Study: NCT04692454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modern acupuncture
Description: use the scalp and ear acupuncture methods to identify diseases and checkpoints and apply them to regulate the immune function of patients with gastroenterological cancers.
Study: NCT02572791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Household cleaning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Household cleaning
Study: NCT02416752

Intervention type: DRUG
Intervention: Remifentanil
Description: The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group

Intervention type: DRUG
Intervention: choice of intra-operative opioids were left to the discretion of anesthesiologist
Study: NCT00605592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic Islets of Langerhans Cell Transplant
Description: Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
Study: NCT04165993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and KN026
Description: 30 mg/kg Q3W KN026 75 mg/m2 docetaxol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 monotherapy
Description: 30 mg/kg Q3W KN026
Study: NCT02900378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril was available in 2.5 mg, 5 mg and 10 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Enalapril
Description: Placebo of Enalapril was available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
Study: NCT00445913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diabetes-suppressive dendritic cell vaccine
Description: The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
Study: NCT04165993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 combination
Description: 30 mg/kg Q3W KN026 5 mg/kg Q3W KN046
Study: NCT00376584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-0524A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER Niacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02555696

Intervention type: DRUG
Intervention: nab-paclitaxel
Description: nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
Study: NCT03298672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDX-1017
Description: Solution of NDX-1017 for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for subcutaneous injection
Study: NCT01791647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin 1500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: myoinositol 1500 mg
Study: NCT00074022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00891319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulator
Description: • 12-week intervention~1. Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~2. Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulator
Description: • 12-week intervention~1. Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~2. Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home.
Study: NCT00407589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303224-A
Description: 1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
Study: NCT04363073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Annabella Breast Pump
Description: Milk will be expressed using Annabella breast pump for 4 consecutive days (at least 24h apart)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Breast Pump
Description: Milk will be expressed using Control breast pump for 4 consecutive days (at least 24h apart)
Study: NCT04020939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY imaging
Description: Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
Study: NCT02462213

Intervention type: OTHER
Intervention: Amyloidosis
Description: Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.

Intervention type: OTHER
Intervention: Cardiac Amyloidosis
Description: Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.
Study: NCT02470026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yohimbine
Description: single low dose treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yohimbine
Description: single low dose treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single control treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single control treatment
Study: NCT02486848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Topical Minoxidil Solution
Description: 5% Topical Minoxidil Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15% Topical Minoxidil Solution
Description: 15% Topical Minoxidil Solution
Study: NCT00626756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiDCO technology
Description: non invasive monitoring of cardiac output
Study: NCT03878446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: Somapacitan injected under the skin once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: Somapacitan injected under the skin once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: Somapacitan injected under the skin once a week.
Study: NCT00445913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: control dendritic cells
Description: The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
Study: NCT01540552

Intervention type: OTHER
Intervention: medical chart review

Intervention type: OTHER
Intervention: medical chart review

Intervention type: PROCEDURE
Intervention: computed tomography

Intervention type: PROCEDURE
Intervention: computed tomography

Intervention type: PROCEDURE
Intervention: computer-aided detection/diagnosis

Intervention type: PROCEDURE
Intervention: computer-aided detection/diagnosis
Study: NCT03228225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele Cardiac Rehabilitation
Description: Comprehensive intervention according to the secondary prevention goals
Study: NCT03426748

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low dose rate prostate brachytherapy
Description: Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High dose rate prostate brachytherapy
Description: Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
Study: NCT01263197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol
Description: administered orally
Study: NCT03878446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin®
Description: Norditropin® injected under the skin once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin®
Description: Norditropin® injected under the skin once a day.
Study: NCT04375228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m\^2 IV weekly for 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 4mg/kg IV once a month for up to 2 doses
Study: NCT03386513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN632
Description: CD123-targeted ADC
Study: NCT04622046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2060
Description: ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
Study: NCT01263197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: administered orally
Study: NCT06735937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low flow anesthesia
Description: Anesthesia management by using low flow anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low flow anesthesia
Description: Anesthesia management by using low flow anesthesia
Study: NCT04069754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Passport to Freedom
Description: 5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections.
Study: NCT03292289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre- and post-operative consultation
Description: Before and between the two interventions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stomatherapy consultation
Description: Clinical exam. At one and six months after the 2nd intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: * QLQ-C30 and QLQ-CR29 at each time defined by the study (one month before and after the first intervention, before the 2nd intervention and at 1, 3, 6 and 12 months after the 2nd intervention)~* Stoma-QoL before and after the 2nd intervention~* LARS score at 1, 3, 6 and 12 months after the 2nd intervention
Study: NCT04307381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donidalorsen
Description: Donidalorsen administered SC
Study: NCT01125943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Intra-arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Description: Intra arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intra arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intra arterial infusion
Study: NCT04308824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clipping
Description: a single clip will be placed in every case of polypectomy for large colorectal polyps

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nebulization of glue
Description: After clipping, a cyanoacrilate glue will be nebulized using a spray catheter
Study: NCT02296151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluteus medius strengthening
Description: Hip abductor, gluteus medius strengthening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluteus medius strengthening
Description: Hip abductor, gluteus medius strengthening

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: iliotibial band stretches
Description: Iliotibial band stretches
Study: NCT03219320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-2925
Description: NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo capsules.